[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580381":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":24,"locations":29,"responsibleParty":65,"collaborators":20,"id":67,"slug":20,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":20,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":20,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Vanda Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Open Label Tradipitant","EXPERIMENTAL","Oral Capsule",[13],"Drug: Tradipitant",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Tradipitant","BID",[9],null,[22],{"name":5,"affiliation":5,"role":23},"STUDY_DIRECTOR",[25],{"name":5,"role":26,"phone":27,"phoneExt":20,"email":28},"CONTACT","202-734-3400","clinicaltrials@vandapharma.com",[30,44,54],{"facility":31,"status":32,"city":33,"state":20,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Vanda Investigational Site","RECRUITING","Leuven","3000","Belgium",{"type":37,"coordinates":38},"Point",[39,40],4.70093,50.87959,{"lat":40,"lon":39},[43],{"name":20,"role":26,"phone":27,"phoneExt":20,"email":20},{"facility":31,"status":32,"city":45,"state":20,"zip":46,"country":35,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Liège","4000",{"type":37,"coordinates":48},[49,50],5.56749,50.63373,{"lat":50,"lon":49},[53],{"name":20,"role":26,"phone":27,"phoneExt":20,"email":20},{"facility":31,"status":32,"city":55,"state":20,"zip":56,"country":57,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Leipzig","04103","Germany",{"type":37,"coordinates":59},[60,61],12.37129,51.33962,{"lat":61,"lon":60},[64],{"name":20,"role":26,"phone":27,"phoneExt":20,"email":20},{"type":66,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100580381",false,"NCT06836557","Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis","A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis","Inclusion Criteria:\n\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Body Mass Index (BMI) of ≥18 and ≤40 kg\u002Fm2\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits\n* Pregnancy or nursing\n* Evidence of uncontrolled blood glucose (including HbA1C \\>11% at screening or metabolic crisis in past 60 days)","ALL","18 Years","70 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"PHASE3","This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.",[84,85,86],"Idiopathic Gastroparesis","Diabetic Gastroparesis","Gastroparesis",[88,89,90,91,92,93,94,95,96,97,98,99],"gastroparesis","idiopathic","diabetic","tradipitant","nausea","vomiting","stomach","motility","functional","NK-1 antagonist","neurokinin 1 receptor","substance p","2025-02-14",{"date":102,"type":103},"2025-02-20","ACTUAL",{"date":105,"type":103},"2024-01-09",{"date":107,"type":78},"2025-12",{"name":5,"class":6},3]